Most patients do well on topical therapy, but innovation in IOP-lowering drops remains essential. One might ask why topical eye drop medications remain the mainstay of glaucoma therapy in the US and ...

New AAV therapy for retinitis pigmentosa completes Phase I/II dosing, aiming to protect cones and slow vision loss; first ...

Collapsing physicians into an undifferentiated “provider” category can obscure differences in expertise and accountability, complicating informed patient navigation of multidisciplinary teams.

Oluwatosin U. Smith, MD, highlights how the foundation provides education, research, and access-to-care for patients and ...

Stephenson, MD, FACS, shares insights on evolving LAL technology and best practices for managing the ocular surface before ...

China’s National Medical Products Administration (NMPA) has granted regulatory approval for 2 next-generation ophthalmic ...

Ocular surface disease (OSD) is a prevalent yet frequently underrecognized challenge in the management of glaucoma. A ...

Andrew G. Lee, MD, and Drew Carey, MD, discuss how optic disc cupping after optic neuritis reflects nerve and ganglion cell ...

The 2025 program built on its evolving reputation as a multispecialty educational forum that successfully integrates ophthalmology and optometry, premium CME content, and a family-friendly format to ...

Edinburgh Biosciences has reported encouraging early outcomes from a structured long-term safety and performance follow-up ...

The IPL's microstructure may serve as a biomarker for early diagnosis of diseases affecting synaptic health, including ...

This finding was based on the results of a study published in BMJ Open Ophthalmology1 that patients with diabetes who were ...